Recent advances in retrometabolic drug design (RMDD) and development

Nicholas Bodor, Peter Buchwald

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

As a general review for the 7th Retrometabolism-Based Drug Design and Targeting Conference, recent developments within this field are briefly reviewed with various illustrative examples from different therapeutic areas. Retrometabolic drug design incorporates two major systematic approaches: the design of soft drugs and of chemical delivery systems (CDS). Both aim to design new, safe drugs with an improved therapeutic index by integrating structure-activity and structure-metabolism relationships; however, they achieve it by different means: whereas soft drugs are new, active therapeutic agents that undergo predictable metabolism to inactive metabolites after exerting their desired therapeutic effect, CDSs are biologically inert molecules that provide enhanced and targeted delivery of an active drug to a particular organ or site through a designed sequential metabolism that involves several steps.

Original languageEnglish
Pages (from-to)395-403
Number of pages9
JournalPharmazie
Volume65
Issue number6
DOIs
StatePublished - Jun 1 2010

Fingerprint

Drug Design
Drug Delivery Systems
Pharmaceutical Preparations
Therapeutic Uses
Structure-Activity Relationship
Therapeutics

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Recent advances in retrometabolic drug design (RMDD) and development. / Bodor, Nicholas; Buchwald, Peter.

In: Pharmazie, Vol. 65, No. 6, 01.06.2010, p. 395-403.

Research output: Contribution to journalArticle

@article{e0e1d0b612aa4120a853bb5ea61c2137,
title = "Recent advances in retrometabolic drug design (RMDD) and development",
abstract = "As a general review for the 7th Retrometabolism-Based Drug Design and Targeting Conference, recent developments within this field are briefly reviewed with various illustrative examples from different therapeutic areas. Retrometabolic drug design incorporates two major systematic approaches: the design of soft drugs and of chemical delivery systems (CDS). Both aim to design new, safe drugs with an improved therapeutic index by integrating structure-activity and structure-metabolism relationships; however, they achieve it by different means: whereas soft drugs are new, active therapeutic agents that undergo predictable metabolism to inactive metabolites after exerting their desired therapeutic effect, CDSs are biologically inert molecules that provide enhanced and targeted delivery of an active drug to a particular organ or site through a designed sequential metabolism that involves several steps.",
author = "Nicholas Bodor and Peter Buchwald",
year = "2010",
month = "6",
day = "1",
doi = "10.1691/ph.2010.0523R",
language = "English",
volume = "65",
pages = "395--403",
journal = "Die Pharmazie",
issn = "0031-7144",
publisher = "Govi-Verlag Pharmazeutischer Verlag GmbH",
number = "6",

}

TY - JOUR

T1 - Recent advances in retrometabolic drug design (RMDD) and development

AU - Bodor, Nicholas

AU - Buchwald, Peter

PY - 2010/6/1

Y1 - 2010/6/1

N2 - As a general review for the 7th Retrometabolism-Based Drug Design and Targeting Conference, recent developments within this field are briefly reviewed with various illustrative examples from different therapeutic areas. Retrometabolic drug design incorporates two major systematic approaches: the design of soft drugs and of chemical delivery systems (CDS). Both aim to design new, safe drugs with an improved therapeutic index by integrating structure-activity and structure-metabolism relationships; however, they achieve it by different means: whereas soft drugs are new, active therapeutic agents that undergo predictable metabolism to inactive metabolites after exerting their desired therapeutic effect, CDSs are biologically inert molecules that provide enhanced and targeted delivery of an active drug to a particular organ or site through a designed sequential metabolism that involves several steps.

AB - As a general review for the 7th Retrometabolism-Based Drug Design and Targeting Conference, recent developments within this field are briefly reviewed with various illustrative examples from different therapeutic areas. Retrometabolic drug design incorporates two major systematic approaches: the design of soft drugs and of chemical delivery systems (CDS). Both aim to design new, safe drugs with an improved therapeutic index by integrating structure-activity and structure-metabolism relationships; however, they achieve it by different means: whereas soft drugs are new, active therapeutic agents that undergo predictable metabolism to inactive metabolites after exerting their desired therapeutic effect, CDSs are biologically inert molecules that provide enhanced and targeted delivery of an active drug to a particular organ or site through a designed sequential metabolism that involves several steps.

UR - http://www.scopus.com/inward/record.url?scp=77955296167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955296167&partnerID=8YFLogxK

U2 - 10.1691/ph.2010.0523R

DO - 10.1691/ph.2010.0523R

M3 - Article

VL - 65

SP - 395

EP - 403

JO - Die Pharmazie

JF - Die Pharmazie

SN - 0031-7144

IS - 6

ER -